MEDICÍNA PRO PRAXI / Med. Praxi. 2023;20(3):157-162 / www.medicinapropraxi.cz 162 MEZIOBOROVÉ PŘEHLEDY Klimakterická pacientka v ambulanci praktického lékaře LITERATURA 1. NAMS Position Statement: The 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-94. 2. Fait T. Hormone replacement therapy: latest developments and clinical practice. Drugs in Context. 2019;8:212551. 3. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44:497-515. 4. Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017;20(4):306-12. 5. Thurston R, Chang Y, Barinas-Mitchel E, et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause. 2017;24(8):886-93. 6. Herber-Gast B, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. BJOG 2015;122:1560-7. 7. Thurston RC, Aizenstein HJ, Derby CA, et al. Menopausal hot flashes and white matter hyperintensities. Menopause. 2016;23:27-32. 8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605. PMID: 9718051. 9. Koire A, Joffe H, Buckley R. Replacement in the Prevention and Treatment of Cognitive Decline, Dementia, and Cognitive Dysfunction of Depression. Harv Rev Psychiatry. 2022; 30(4):215-22. 10. Kim J, Chang JH, Jeong MJ, et al. A systematic review and metaanalysis of effects of menopause hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631. 11. Fait T, Vrablik M. Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. Neuro Endocrinol Lett. 2012;33(Suppl. 2):17-21. 12. Fait T. Klíč k nasazení HRT. Gynek Porod. 2020;4(3):133-6. 13. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426-46. 14. Tan DA, Dayu ARB. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric. 2022;25(4):362-8. 15. Ruan X, Mueck AO. Primary choice of estrogen and progesteron as components of HRT. Climacteric. 2022;25(5):443-52. 16. Fournier A, Berino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-11. 17. Fait T. Tibolon – jediný zástupce skupiny STEARs. Cas Lek Ces. 2019;158:107-111. 18. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003 Aug 9;362(9382):42832. doi: 10.1016/S0140-6736(03)14066-4. PMID: 12927428. 19. Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405-20. 20. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women´s Health Initiative randomized trial. JAMA. 2003;290(13):1729-38. 21. Robbins JA, Argaki A, Crandall CJ, et al. WHI trials: interaction of calcium and vitamin D with hormone therapy. Menopause. 2014;21(2):116-23. 22. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fracture: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891-7. 23. Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461-70. 24. NAMS Management of symptomatic vulvovaginal atrophy, position statement of the North American Menopause Society. Menopause. 2013;20:888-902. 25. Ulrich LSG, Naessen T, Elia D, et al. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;1:228-237. 26. Sirotkin AV, Harrath AH. Phytoestrogens and their effects. Eur J Pharmacol. 2014;741:230-6. 27. Duncan AM, Phipps WR, Kurzer MS. Phyto-estrogens. Best Practice Research Clin Endocrin Metab. 2003;17(2):253-71. 28. Ye YB, Tang XY, Verbruggen M, Su YX. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women. Eur J Nutr. 2006;3:1-8. 29. Atkinson C, Newton KM, Bowless EJ, et al. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in USA. Am J Clin Nutr. 2008;87:679-87. 30. Labos G, Trakakis E, Pliatsika P, et al. Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. J Endocrinol Invest. 2013;36:521-6. 31. Sánchez-Borrego R, Mendoza N, Llaneza P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms. Climacteric. 2015;10:1-8. 32. Fait T, Borovsky M. DT56a in treatment of climacteric syndrome in a Central European population sample. Bratislava Medical Journal. 2021;122(5):301-4. 33. Hellström AC, Muntzing J. The pollen extract Femal – a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825-9. 34. Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2019;35(4):360-3. 35. Llaneza P, Garcia-Portilla P, Llaneza-Suarez D, et al. Depressive disorders and the menopause transition. Maturitas. 2012;71:120-30. 36. Toffol E, Kekinheimo O, Patronen T. Hormone therapy and mood in in perimenopausal women. Menopause. 2015;22(5):564-78. 37. Liu T, Chen S, Milke GI, et al. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. Climacteric. 2022;29:1-10. Připravujeme do příští Medicíny pro praxi Přehledové články Revmatoidní artritida – diagnostika a léčba Celiakie v dnešní době Mezioborové přehledy Pohled na užívání ACE inhibitorů + sartanu – diabetická nefropatie – kdy použít Spolupráce poskytovatele zdravotnické záchranné služby a ambulantního sektoru Farmakoterapie aktuálně Psychohygiena praktického lékaře Pro sestry Perkutánní endoskopická gastrostomie, jejunostomie (PEG, PEJ) v domácím ošetření z pohledu sestry Nejčastější omyly v diagnostice Diabetologie – úskalí diagnózy cukrovky, rozlišení typů a mnoho dalších… ▼ VYJDE V ZÁŘÍ
RkJQdWJsaXNoZXIy NDA4Mjc=